biote Yönetim
Yönetim kriter kontrolleri 2/4
biote CEO'su Bret Christensen, Feb2025 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 5.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.7% maaş ve 87.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler $ 87.70K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 4 yıldır.
Anahtar bilgiler
Bret Christensen
İcra Kurulu Başkanı
US$5.1m
Toplam tazminat
| CEO maaş yüzdesi | 12.65% |
| CEO görev süresi | 1.3yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 2.2yrs |
| Yönetim Kurulu ortalama görev süresi | 4yrs |
Son yönetim güncellemeleri
Recent updates
Yeni Anlatı • May 22
biote Corp. (BTMD) - Regulatory Tailwind Meets Operational Reset: A Mispriced Recovery
Introduction biote Corp. (NASDAQ: BTMD) is a U.S.-based hormone optimization company operating through a unique asset-light model.
Anlatı Güncellemesi • May 19
BTMD: Recall And Investment Reset Will Support 2026 Revenue Recovery Potential
Analysts have trimmed their average price targets for biote to a lower range, generally cutting expectations by about $1 per share as they factor in the impact of a voluntary recall, higher planned investment and a slower pace of new clinic growth before a potential sales recovery in 2026. Analyst Commentary Across recent research, bullish analysts have adjusted their models to reflect the recall, higher planned spending, and a slower clinic ramp, yet many still see room for value creation if management executes on its plan through 2026.
Anlatı Güncellemesi • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.Anlatı Güncellemesi • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.Anlatı Güncellemesi • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.
Anlatı Güncellemesi • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.Anlatı Güncellemesi • Mar 06
BTMD: Affordable Medicines Theme Will Drive Upside Despite Recent Cautious Reassessment
Analysts recently trimmed their 12 month price target on biote to $5 from $6, with the change tied to updated views on discount rates, revenue growth potential, profit margins, and a slightly higher assumed future P/E multiple, while still citing the broader affordable medicines theme as a key part of the thesis heading into 2026. Analyst Commentary Recent Street research has highlighted a more cautious tone around biote, with the 12 month price target trimmed to $5 from $6.Anlatı Güncellemesi • Feb 20
BTMD: Affordable Medicines Theme Will Support Upside Case Despite Lower Street Expectations
Analysts have trimmed their price target on biote to $5 from $6, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E. They continue to highlight the company’s fit within the broader affordable medicines theme.Anlatı Güncellemesi • Feb 05
BTMD: Affordable Medicines Theme Will Support Upside Potential Despite Lowered Expectations
Narrative update on biote Analysts have trimmed their price target on biote to US$5 from US$6, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while still highlighting affordable medicines as a supportive theme heading into 2026. Analyst Commentary Recent research reflects a more cautious stance on biote's share price while still pointing to the affordable medicines theme as an important support for the story heading into 2026.Anlatı Güncellemesi • Jan 22
BTMD: Affordable Medicines Theme Will Support Reassessed Outlook Into 2026
Analysts recently trimmed their price target on biote to $5 from $6, citing a mix of updated assumptions on fair value, discount rate, growth, margins, and future P/E expectations as they reassessed the stock within the broader affordable medicines theme heading into 2026. Analyst Commentary Recent Street research on Biote has focused on recalibrating expectations around valuation, execution, and growth, with some Bearish analysts taking a more cautious stance even as the broader affordable medicines theme remains in focus heading into 2026.Anlatı Güncellemesi • Jan 07
BTMD: Affordable Medicines Theme And Buybacks Will Support Upside Potential
Analysts have trimmed their price target on biote to $5 from $6, citing a still supportive view on the affordable medicines theme, even as they fine tune assumptions for revenue growth, margins, and future P/E expectations. Analyst Commentary Even with the trimmed price target, bullish analysts continue to frame biote within the affordable medicines theme, suggesting they still see room for the shares to reflect that positioning over time.Anlatı Güncellemesi • Dec 13
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.Seeking Alpha • Sep 10
Restructuring At Biote Will Drive Greater Growth And Profitability
Summary I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance. Valuation remains attractive with significant upside to intrinsic value, but investors should monitor debt levels, potential dilution, and execution risks. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
One of the biggest stories of last week was how biote Corp. ( NASDAQ:BTMD ) shares plunged 26% in the week since its...Anlatı Güncellemesi • Aug 08
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.Analiz Makalesi • Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
NasdaqGM:BTMD 1 Year Share Price vs Fair Value Explore biote's Fair Values from the Community and select yours biote...Analiz Makalesi • May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
biote Corp. ( NASDAQ:BTMD ) investors will be delighted, with the company turning in some strong numbers with its...Analiz Makalesi • May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
With a price-to-earnings (or "P/E") ratio of 37.3x biote Corp. ( NASDAQ:BTMD ) may be sending very bearish signals at...Analiz Makalesi • Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
biote Corp. ( NASDAQ:BTMD ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Analiz Makalesi • Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.9x biote Corp. ( NASDAQ:BTMD ) is definitely a stock...
Yeni Anlatı • Sep 26
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.Seeking Alpha • Sep 27
biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Truist has initiated biote Corp. (NASDAQ:BTMD) with a buy rating highlighting the company's leadership in providing bioidentical hormone replacement therapy to improve hormonal imbalance. The firm has a $10 price target (~138% upside based on Monday's close). Analyst Gregory Fraser said that the company's platform "provides physicians with effective treatment options as well as a source of income" and added that the model has led to revenue and EBITDA growth. He noted that biote's (BTMD) growth strategy is focused on increasing utlilization of both existing and new partner clinics. Truist conducted a survey of 25 physicians who use biote's (BTMD) bioidentical hormone replacement therapy and found they expect to prescribe more of the company's pellet therapy over the next year. Seeking Alpha's Quant Rating views biote (BTMD) as a strong buy.Seeking Alpha • Sep 07
Biote partners with IMAC Holdings
biote Corp (NASDAQ:BTMD) said it had entered into a partnership with IMAC Holdings, to add the latter's services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. The Company said it had begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September. "We are excited to add Biote’s services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. IMAC Holdings deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$16m |
| Dec 31 2025 | US$5m | US$642k | US$27m |
Tazminat ve Piyasa: Bret 'nin toplam tazminatı ($USD 5.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 624.15K ).
Tazminat ve Kazançlar: Bret şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Bret Christensen (54 yo)
1.3yrs
Görev süresi
US$5,075,718
Tazminat
Mr. Bret Christensen is Director of Neurolutions, Inc. (also known as Kandu, Inc.) from October 2025. Mr. Christensen serves as CEO & Director of biote Corp. since February 1, 2025. He served as Chief Exec...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.08m | 0.12% $ 87.7k | |
| CFO & Chief Business Officer | 2.3yrs | US$1.45m | Veri yok | |
| VP of Business Development | 4.9yrs | US$1.67m | Veri yok | |
| Chief Information Officer | 2.1yrs | Veri yok | Veri yok | |
| Chief Marketing Officer | 1.3yrs | Veri yok | Veri yok | |
| Chief Digital Officer | 5.3yrs | Veri yok | Veri yok | |
| Head of Nutraceuticals | 4yrs | Veri yok | Veri yok | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| SVP of Strategy & Commercial Operations | less than a year | Veri yok | Veri yok |
2.2yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: BTMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.08m | 0.12% $ 87.7k | |
| Chief Clinical Advisor & Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4yrs | US$323.93k | 8.18% $ 5.8m | |
| Non-Executive Chairman of the Board | 5.3yrs | US$1.56m | 0.36% $ 251.4k | |
| Independent Director | 3.5yrs | US$326.74k | 0.24% $ 166.9k | |
| Lead Independent Director | less than a year | US$389.35k | Veri yok | |
| Chair of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.8yrs | US$313.38k | 0.53% $ 375.1k | |
| Independent Director | 4yrs | US$327.44k | 0.21% $ 149.2k | |
| Senior Medical Advisor & Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok |
4.0yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BTMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/26 15:22 |
| Gün Sonu Hisse Fiyatı | 2026/05/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
biote Corp. 6 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |